Sarepta Therapeutics’ Reorganization Boosts Investor Confidence

Sarepta agrees to FDA’s black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.

Latest Ratings for SRPT

DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Mar 2022RBC CapitalMaintainsOutperform Feb 2022Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for SRPT

View the Latest Analyst Ratings

read more